HCA
VRTX icon

Harbour Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Harbour Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Buy
6,051
+57
+1% +$25.3K 0.53% 50
2026
Q1 		$2.62M Buy
5,994
+61
+1% +$28.4K 0.5% 54
2025
Q4 		$2.68M Sell
5,933
-248
-4% -$107K 0.55% 49
2025
Q3 		$2.54M Sell
6,181
-186
-3% -$77.7K 0.52% 55
2025
Q2 		$2.91M Buy
6,367
+145
+2% +$66.8K 0.61% 46
2025
Q1 		$3.01M Sell
6,222
-20
-0.3% -$9.32K 0.74% 37
2024
Q4 		$2.54M Sell
6,242
-44
-0.7% -$20.4K 0.57% 50
2024
Q3 		$2.94M Buy
6,286
+86
+1% +$41.3K 0.68% 41
2024
Q2 		$2.92M Buy
6,200
+665
+12% +$289K 0.69% 43
2024
Q1 		$2.27M Buy
5,535
+68
+1% +$28.7K 0.56% 45
2023
Q4 		$2.25M Buy
5,467
+44
+0.8% +$16.3K 0.62% 44
2023
Q3 		$1.89M Buy
5,423
+305
+6% +$107K 0.57% 47
2023
Q2 		$1.78M Sell
5,118
-202
-4% -$68.1K 0.52% 48
2023
Q1 		$1.68M Buy
5,320
+419
+9% +$126K 0.51% 49
2022
Q4 		$1.4M Buy
4,901
+443
+10% +$135K 0.47% 58
2022
Q3 		$1.31M Buy
4,458
+1,118
+33% +$322K 0.46% 59
2022
Q2 		$941K Buy
3,340
+1,620
+94% +$434K 0.31% 81
2022
Q1 		$449K Buy
+1,720
New +$408K 0.12% 152

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Harbour Capital Advisors's VRTX Position: Q2 2026 in Review

Harbour Capital Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.95% in Q2 2026, buying an estimated $25.3K and bringing the position to 6,051 shares worth $2.94M. The position accounts for 0.53% of the portfolio, ranked #50.

Harbour Capital Advisors first reported a position in VRTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.01M in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Harbour Capital Advisors held 6,051 shares of Vertex Pharmaceuticals worth $2.94M as of Q2 2026.
  • Harbour Capital Advisors bought 57 Vertex Pharmaceuticals shares in Q2 2026, an estimated $25.3K.
  • Vertex Pharmaceuticals made up 0.53% of Harbour Capital Advisors's portfolio in Q2 2026, its #50 holding.
  • Harbour Capital Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Harbour Capital Advisors's Vertex Pharmaceuticals position peaked at $3.01M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Harbour Capital Advisors's 13F filing for Q2 2026, filed 15 Jul 2026.